The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.
Simple Explanation
The National Cancer Institute is thinking about letting Ziopharm Oncology use special recipes they came up with to make medicine that can help fight cancer. They want to hear from people who have thoughts or ideas about this by February 9, 2021.